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Summary
Invasive aspergillosis (Ia) is a disease of the 
immunocompromised with a predilection for the lungs, 
although dissemination to all organs is possible. Its 
diagnosis remains a challenge due to the absence of 
specific clinical manifestations and laboratory findings. 
In most cases, diagnosis is eventually made via invasive 
methods. It carries with it a high mortality due to late 
diagnosis and delayed treatment. Here, we report 
a fascinating case of a young, otherwise healthy, 
immunocompetent patient that presented to us with 
superior vena cava syndrome and a mediastinal mass. 
It was anticipated that a malignancy would be found 
on further workup but, in fact, what was eventually 
discovered was a case of Ia. our report accentuates 
the significance of including Ia as a differential while 
diagnosing a mediastinal mass in an immunocompetent 
host as patient outcome is determined by timely 
diagnosis and treatment.
BaCkground 
Aspergillosis comprises a spectrum of diseases 
related to host factors.1–3 Invasive aspergillosis 
(IA) is a disease of concern due to high mortality 
in transplant recipients and patients with haemato-
logical malignancies. Although rare, its occurrence 
has been reported in immunocompetent hosts, with 
multisystem involvement.4–6 Here, we present a 
case of a young immunocompetent man presenting 
with signs of superior vena cava (SVC) obstruction 
and a mediastinal mass. Suspicion of a malignancy 
was high but on biopsy was found to have IA of the 
mediastinum.
CaSe preSenTaTion
A 28-year-old man was referred to our pulmonary 
outpatient clinic (Aga Khan University Hospital, 
Karachi) for the workup of a mediastinal mass. He 
had a 12-month history of right-sided chest pain, 
Figure 1 Right anterior neck and chest wall showing 
prominent neck and chest wall veins and mediastinotomy 
scar.
Figure 2 Chest X-ray showing widened mediastinum, 
elevated right hemidiaphragm and blunting of the right 
costophrenic angle.
Figure 3 CT of the chest. (A) Lung window showing 
right anterior mediastinal mass with right-sided effusion. 
(B) Mediastinal window showing mediastinal mass 
occluding right main bronchus. (C) Coronal section 
showing invasion of the mediastinal structures.
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with radiation to the back. He also complained of shortness of 
breath, reduced appetite, weight loss, difficulty swallowing and 
swelling of his face and neck for the past 5 months. He denied 
fever, night sweats, cough or past tuberculosis (TB) contact. He 
had a history of smoking in the distant past, that is, 2 years of 
smoking around 10 years ago. He denied alcohol and illicit drug 
use. He sought medical attention 6 months after his symptoms 
began in his hometown. He was started on treatment for asthma, 
that is, inhaled corticosteroids and inhaled long-acting beta-ag-
onist and a 3-week tapering dose of oral prednisolone (starting 
at 10 mg twice a day) with no improvement whatsoever. A chest 
X-ray (CXR) was ordered and a suspicious finding on that led to 
a CT of the thorax, which showed a mediastinal mass. Despite 
two negative sputum samples for acid-fast bacilli (AFB), he was 
started on empiric antituberculous therapy. This was discon-
tinued after 3 weeks as there was no clinical improvement.
He was then referred to us for further workup and manage-
ment with a strong suspicion of malignancy (likely lymphoma).
On initial assessment, vital signs were within normal values. 
There was evidence of congested neck, prominent chest wall 
veins and facial plethora (figure 1).
Chest examination revealed absent breath sounds on the 
lower one-third of the right posterior chest and an otherwise 
unremarkable cardiovascular and systemic examination.
inveSTigaTionS
Laboratory tests were normal. CXR was concerning for a 
widened mediastinum and right-sided effusion (figure 2).
Diagnostic thoracentesis revealed a lymphocyte dominant 
exudate, a white cell count of 6.673×109/L (lymphocytes 95%), 
protein of 4.8 g/dL, glucose of 88 mg/dL and Lactate dehydro-
genase (LDH) of 323 U/L. Pleural fluid cytology revealed no 
malignant cells. Serological testing for HIV was negative. Serum 
immunoglobulin (IgG, IgA, IgM) levels were within normal 
range.
CT thorax showed an 11×9×8 cm mass centred in the ante-
rior and middle mediastinum, more on the right side. It showed 
invasion of the right atrium, right pulmonary artery with partial 
Figure 4 Periodic acid-Schiff stain highlighting mostly fungal spores, 
rare hyphae seen.
Figure 5 Periodic acid-Schiff stain highlighting mostly fungal spores, 
rare hyphae seen.
Figure 6 Gomori methenamine-silver stain, highlighting fungal 
bodies.
Figure 7 Aspergillus colonies.
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invasion of the left atrium and left inferior pulmonary vein. 
Partial obliteration of the right main stem bronchus was noted 
along with narrowing of the SVC and prominent collaterals 
(figure 3A–C).
ouTCome and Follow-up
He underwent anterior mediastinotomy, with mediastinal 
mass biopsy, revealing non-necrotising granulomas, with 
multinucleated giant cells and histiocytes. Scant fragments 
of fibrocollagenous tissue noted. Periodic acid-Schiff and 
Gomori methenamine-silver stains highlighted occasional 
septate fungal hyphae (figures 4, 5 and 6). Mycology cultures 
grew the Aspergillus flavus complex (figure 7). Mediastinal tissue 
AFB smear and culture were negative.
Therapy with oral voriconazole 400 mg twice a day for 1 day 
followed by 200 mg twice a day was started after histological 
confirmation, and the patient was asked to follow up in 4 and 
then 8 weeks, while continuing therapy. Patient showed marked 
improvements in symptoms with progressive weight gain and 
increased oral intake. Repeat CT scan is planned at 6 months to 
look for mass resolution.
diSCuSSion
To the best of our knowledge, this is the second case of SVC 
obstruction secondary to IA of the mediastinum in an immu-
nocompetent host published in the literature. Association with 
other infectious diseases namely syphilis, TB, histoplasmosis and 
actinomycosis have been described.
Aspergillus is a spore-forming saprophytic fungus, ubiquitous 
to the environment. With approximately 200 species, Aspergillus 
fumigatus is the most commonly isolated pathogen.
Aspergillus species cause a broad spectrum of disease, ranging 
from hypersensitivity reactions to direct angioinvasion. The lung 
is the most common site of infection with disease ranging from 
allergic bronchopulmonary aspergillosis, chronic necrotising 
pneumonia, aspergilloma and IA.6
IA is primarily a disease of immunocompromised patients, with 
prolonged neutropenia constituting a predominant risk factor,7 
followed by haematopoietic stem cell transplants or solid organ 
transplants (especially lung transplantation) and advanced 
AIDS.8 9 In the above population of patients, host factors govern 
the risk and clinicopathological features of invasive disease.1 2 
Rarely invasive pulmonary aspergillosis may complicate chronic 
obstructive pulmonary disease, particularly when treated with 
oral corticosteroids (OCS), bacterial or viral pneumonia, sepsis, 
liver failure, alcoholism or sinusitis.10–12
Our patient’s laboratory findings revealed no evidence of 
neutropenia or immunosuppression, raising a suspicion of 
whether his 2-year smoking history or 3-week history of OCS 
use could have led to some abnormalities in the pulmonary 
defence mechanism. This seemed an unlikely possibility as the 
patient was symptomatic months before inhaled or OCS therapy 
was prescribed.
The respiratory tract remains the primary focus of disease, 
with poor disease control leading to mediastinal extension and 
haematogenous dissemination that can involve any organ.13
The diagnosis of IA remains a challenge due to the absence 
of specific clinical manifestations, non-pathognomonic radio-
logical findings and poor sensitivity of sputum cultures. In 
most cases, diagnosis is made by tissue isolation through inva-
sive methods, as was the case in our patient. However, we 
felt attempting a less invasive approach namely image-guided 
fine-needle aspiration would have yielded the same results and 
should have been attempted first. Serological tests are adjuncts 
to support or exclude the diagnosis in the appropriate clinical 
context; however, they cannot be solely relied on for a definitive 
diagnosis.
Published literature highlights the poor, usually fatal outcome 
in patients with disease involving the mediastinum, despite initi-
ation of antifungal therapy.14–16 This particularly holds truth in 
cases with delayed diagnosis leading to treatment delay and fatal 
outcomes. In this case, the patient continues to have a favourable 
outcome, with ongoing follow-up.
Treatment is often prolonged, with the duration of treatment 
determined empirically, depending on the extent of IA, the response 
to therapy and the immune status of the patient. Voriconazole is 
the first-line therapy for IA, with treatment duration depending 
on disease burden and host immunocompetence. The Infectious 
Diseases Society of America recommends 6 to 12 weeks of therapy 
for pulmonary aspergillosis.16 In immunosuppressed patients, 
therapy should be continued throughout the period of immuno-
suppression and until the resolution of lesions.16 Surgical treatment 
is reserved for patients who do not tolerate antifungal therapy or 
have residual localised but active lesions, despite adequate anti-
fungal therapy.
This case highlights the importance of including the suspi-
cion of IA in the differential diagnosis of a mediastinal mass 
presenting with signs of SVC syndrome irrespective of immune 
status, where TB and malignancy represent valid possibilities, 
as disease outcome is directly linked with early diagnosis and 
therapy.17 Early and timely treatment prevents future complica-
tions and death.
learning points
 ► Invasive aspergillosis (IA) is a rare but important 
consideration in immunocompetent patients presenting with 
signs of superior vena cava obstruction and a mediastinal 
mass.
 ► Suspicion of IA in a patient, who does not respond to 
antibiotic or antituberculous therapy, is imperative in early 
diagnosis, allowing timely initiation of aggressive antifungal 
therapy and increasing the chances of a favourable outcome.
 ► Imaging-guided percutaneous needle biopsy of mediastinal 
masses should be attempted first before reverting to a more 
invasive approach namely surgery.
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